Hong Seok

Principal Researcher at Abion

Presenter

ABION, INC., founded in 2007, is a biopharmaceutical company dedicated to the development of innovative companion diagnostic-based drugs targeting first-in-class and best-in-class categories in the global market. Our mission is underpinned by four core mottos: integrity, professionalism, innovation, and sustainability. These values are central to our approach in creating and validating new drug entities through rigorous protocols and consolidating proof of concept. Integrity guides our commitment to ethical practices and transparency throughout the drug development process. Professionalism drives our adherence to the highest standards in scientific and regulatory practices. Innovation is at the heart of our efforts, enabling us to push the boundaries of precision medicine and address unmet medical needs effectively. Sustainability ensures that our practices support long-term success and contribute positively to the healthcare system and environment. Our dedication to these principles enables us to make significant strides in precision medicine, which we believe will greatly benefit the public healthcare system. The synergistic nature of our collaborations supports the advancement of Abion’s therapeutic pipelines, which are focused primarily on oncology. We are actively developing four major pipelines: ABN401 (vabametkib), ABN202, and ABN501, each designed to address critical areas in cancer treatment and beyond.